دورية أكاديمية
أعرض في EDS

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania.

التفاصيل البيبلوغرافية
العنوان: Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania.
المؤلفون: Miron AA; Faculty of Medicine, Transilvania University of Braşov, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, 500123 Brașov, Romania., Ifteni PI; Faculty of Medicine, Transilvania University of Braşov, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, 500123 Brașov, Romania., Teodorescu A; Faculty of Medicine, Transilvania University of Braşov, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, 500123 Brașov, Romania., Petric PS; Faculty of Medicine, Transilvania University of Braşov, 500036 Brașov, Romania.; Spitalul Clinic de Psihiatrie și Neurologie Brașov, 500123 Brașov, Romania.
المصدر: Healthcare (Basel, Switzerland) [Healthcare (Basel)] 2022 Jul 07; Vol. 10 (7). Date of Electronic Publication: 2022 Jul 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101666525 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9032 (Print) Linking ISSN: 22279032 NLM ISO Abbreviation: Healthcare (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: Long acting injectable antipsychotics (LAIs) are considered the ideal treatment for schizophrenia, especially for young patients with high rates of non-adherence. In the current COVID-19 pandemic, it has been reported that the administration of LAIs decreased in some areas. The aim of this study was to evaluate the impact of COVID-19 pandemic on the initiation of LAIs. This is a retrospective mirror- image study covering a total period of 24 months: 12 months before and 12 months after the declaration of COVID-19 pandemic on March 11, 2020. During the study period, out of 218 patients admitted with schizophrenia, only 15 (1.3%) received LAIs at discharge. There was a 48.3% reduction in LAIs initiation compared to the pre-pandemic period (29 LAIs initiations in 2019 from 224 admissions). Despite the 27% reduction in the total number of admissions (1500 in 2019 vs. 1100 in 2020), the number of admissions with schizophrenia remained almost the same (224 in 2019 vs. 218 in 2020). COVID-19 pandemic brought an important challenge in the treatment of patients with schizophrenia, especially in the initiation of LAIs. This could have an important impact on the relapse rate in the next period.
References: Acta Psychiatr Scand. 1997 Jun;95(6):464-8. (PMID: 9242840)
Schizophr Res. 2020 Jun;220:265-266. (PMID: 32349886)
Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99. (PMID: 24167680)
J Clin Psychiatry. 2016;77(suppl 3):1-24. (PMID: 27732772)
Am J Psychiatry. 2020 Sep 1;177(9):868-872. (PMID: 32867516)
Schizophr Res Treatment. 2012;2012:791468. (PMID: 22966445)
J Clin Psychiatry. 2014 Nov;75(11):1254-60. (PMID: 25188501)
Br J Psychiatry. 2022 Dec;221(6):748-757. (PMID: 35968915)
J Med Econ. 2015 May;18(5):357-65. (PMID: 25525771)
BMC Psychiatry. 2021 Dec 20;21(1):633. (PMID: 34930204)
Can J Psychiatry. 2013 May;58(5 Suppl 1):14S-22S. (PMID: 23945063)
Psychiatry Res. 2020 Jul;289:113069. (PMID: 32413707)
BJPsych Open. 2017 Aug 10;3(4):186-192. (PMID: 28811926)
Schizophr Res. 2018 Jul;197:274-280. (PMID: 29274734)
Br J Psychiatry. 2001 Oct;179:300-7. (PMID: 11581109)
Psychiatry Res. 2010 Jan 30;175(1-2):58-62. (PMID: 20004980)
J Psychopharmacol. 2010 Oct;24(10):1473-82. (PMID: 19477883)
CNS Drugs. 2016 Aug;30(8):689-701. (PMID: 27255405)
BMC Psychiatry. 2022 Jan 10;22(1):32. (PMID: 35012512)
Neuropsychiatr Dis Treat. 2021 Oct 02;17:3053-3060. (PMID: 34629871)
Neuropsychiatr Dis Treat. 2022 May 04;18:977-983. (PMID: 35547265)
Schizophr Res. 2020 Aug;222:532-533. (PMID: 32389613)
BMC Psychiatry. 2013 Oct 16;13:261. (PMID: 24131801)
Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. (PMID: 25360245)
Front Pharmacol. 2022 Apr 27;13:886652. (PMID: 35571118)
Ther Adv Psychopharmacol. 2014 Oct;4(5):179-85. (PMID: 25360242)
Psychiatr Q. 2022 Jun;93(2):627-635. (PMID: 35235126)
JAMA Psychiatry. 2017 Jul 1;74(7):686-693. (PMID: 28593216)
Front Psychiatry. 2021 Dec 07;12:767756. (PMID: 34950069)
فهرسة مساهمة: Keywords: long-acting injectable antipsychotics; pandemic; relapse; schizophrenia
تواريخ الأحداث: Date Created: 20220727 Latest Revision: 20230918
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9316377
DOI: 10.3390/healthcare10071265
PMID: 35885792
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9032
DOI:10.3390/healthcare10071265